A validated and standardized pseudotyped microneutralization assay as a safe and powerful tool to measure LASSA virus neutralising antibodies for vaccine development and comparison [version 2; peer review: 2 approved]
Background Over the past few decades, World Health Organization (WHO) has made massive efforts to promote the development of a vaccine against Lassa virus (LASV), one of the top ten priority pathogens for research and development under the WHO R&D Blueprint for Emerging Infections. To date, seve...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
F1000 Research Ltd
2024-10-01
|
| Series: | F1000Research |
| Subjects: | |
| Online Access: | https://f1000research.com/articles/13-534/v2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850063019477827584 |
|---|---|
| author | Alessandro Manenti Emanuele Montomoli Francesca Dapporto Maria Altamura Nigel Temperton Pietro Piu Claudia Semplici Eleonora Molesti Vittoria Forconi Roberta Antonelli |
| author_facet | Alessandro Manenti Emanuele Montomoli Francesca Dapporto Maria Altamura Nigel Temperton Pietro Piu Claudia Semplici Eleonora Molesti Vittoria Forconi Roberta Antonelli |
| author_sort | Alessandro Manenti |
| collection | DOAJ |
| description | Background Over the past few decades, World Health Organization (WHO) has made massive efforts to promote the development of a vaccine against Lassa virus (LASV), one of the top ten priority pathogens for research and development under the WHO R&D Blueprint for Emerging Infections. To date, several vaccines are at different stages of development. In this scenario, a validated and standardised assay to measure LASV neutralising antibodies is urgently needed for vaccine development and comparison. Methods The neutralisation assay remains the gold standard for determining antibody efficacy. Here we have proposed a safe and validated pseudotyped neutralisation assay for LASV, taking advantage of the development of the first WHO International Standard and Reference Panel for Anti-Lassa Fever (NIBSC code 21/332). Results and Conclusions The proposed results demonstrate that the pseudotyped luciferase neutralisation assay is a specific serological test for the measurement of LASV neutralising antibodies without cross-reacting with standard sera specific for heterologous viral infections. In addition, the assay is accurate, precise, and linear according to criteria and statistical analyses defined and accepted by international guidelines. |
| format | Article |
| id | doaj-art-b121c6ddc3e545eeba3dd457cb08a97c |
| institution | DOAJ |
| issn | 2046-1402 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | F1000 Research Ltd |
| record_format | Article |
| series | F1000Research |
| spelling | doaj-art-b121c6ddc3e545eeba3dd457cb08a97c2025-08-20T02:49:46ZengF1000 Research LtdF1000Research2046-14022024-10-011310.12688/f1000research.149578.2172528A validated and standardized pseudotyped microneutralization assay as a safe and powerful tool to measure LASSA virus neutralising antibodies for vaccine development and comparison [version 2; peer review: 2 approved]Alessandro Manenti0Emanuele Montomoli1Francesca Dapporto2Maria Altamura3Nigel Temperton4Pietro Piu5Claudia Semplici6Eleonora Molesti7Vittoria Forconi8https://orcid.org/0009-0008-3720-3879Roberta Antonelli9https://orcid.org/0000-0001-6884-7847Vismederi, Siena, Italy, 53100, ItalyDepartment of Molecular and Developmental Medicine, University of Siena, Siena, ItalyVismederi, Siena, Italy, 53100, ItalyVismederi, Siena, Italy, 53100, ItalyViral Pseudotype Unit, Medway School of Pharmacy,, University of Kent and Greenwich at Medway, Chatham, Kent, UKVismederi, Siena, Italy, 53100, ItalyVismederi, Siena, Italy, 53100, ItalyVismederi, Siena, Italy, 53100, ItalyLife-Science, University of Siena, Siena, ItalyVismederi, Siena, Italy, 53100, ItalyBackground Over the past few decades, World Health Organization (WHO) has made massive efforts to promote the development of a vaccine against Lassa virus (LASV), one of the top ten priority pathogens for research and development under the WHO R&D Blueprint for Emerging Infections. To date, several vaccines are at different stages of development. In this scenario, a validated and standardised assay to measure LASV neutralising antibodies is urgently needed for vaccine development and comparison. Methods The neutralisation assay remains the gold standard for determining antibody efficacy. Here we have proposed a safe and validated pseudotyped neutralisation assay for LASV, taking advantage of the development of the first WHO International Standard and Reference Panel for Anti-Lassa Fever (NIBSC code 21/332). Results and Conclusions The proposed results demonstrate that the pseudotyped luciferase neutralisation assay is a specific serological test for the measurement of LASV neutralising antibodies without cross-reacting with standard sera specific for heterologous viral infections. In addition, the assay is accurate, precise, and linear according to criteria and statistical analyses defined and accepted by international guidelines.https://f1000research.com/articles/13-534/v2Lassa virus (LASV) International Standard and Reference Panel for Anti-Lassa Fever neutralisation assay international guidelineseng |
| spellingShingle | Alessandro Manenti Emanuele Montomoli Francesca Dapporto Maria Altamura Nigel Temperton Pietro Piu Claudia Semplici Eleonora Molesti Vittoria Forconi Roberta Antonelli A validated and standardized pseudotyped microneutralization assay as a safe and powerful tool to measure LASSA virus neutralising antibodies for vaccine development and comparison [version 2; peer review: 2 approved] F1000Research Lassa virus (LASV) International Standard and Reference Panel for Anti-Lassa Fever neutralisation assay international guidelines eng |
| title | A validated and standardized pseudotyped microneutralization assay as a safe and powerful tool to measure LASSA virus neutralising antibodies for vaccine development and comparison [version 2; peer review: 2 approved] |
| title_full | A validated and standardized pseudotyped microneutralization assay as a safe and powerful tool to measure LASSA virus neutralising antibodies for vaccine development and comparison [version 2; peer review: 2 approved] |
| title_fullStr | A validated and standardized pseudotyped microneutralization assay as a safe and powerful tool to measure LASSA virus neutralising antibodies for vaccine development and comparison [version 2; peer review: 2 approved] |
| title_full_unstemmed | A validated and standardized pseudotyped microneutralization assay as a safe and powerful tool to measure LASSA virus neutralising antibodies for vaccine development and comparison [version 2; peer review: 2 approved] |
| title_short | A validated and standardized pseudotyped microneutralization assay as a safe and powerful tool to measure LASSA virus neutralising antibodies for vaccine development and comparison [version 2; peer review: 2 approved] |
| title_sort | validated and standardized pseudotyped microneutralization assay as a safe and powerful tool to measure lassa virus neutralising antibodies for vaccine development and comparison version 2 peer review 2 approved |
| topic | Lassa virus (LASV) International Standard and Reference Panel for Anti-Lassa Fever neutralisation assay international guidelines eng |
| url | https://f1000research.com/articles/13-534/v2 |
| work_keys_str_mv | AT alessandromanenti avalidatedandstandardizedpseudotypedmicroneutralizationassayasasafeandpowerfultooltomeasurelassavirusneutralisingantibodiesforvaccinedevelopmentandcomparisonversion2peerreview2approved AT emanuelemontomoli avalidatedandstandardizedpseudotypedmicroneutralizationassayasasafeandpowerfultooltomeasurelassavirusneutralisingantibodiesforvaccinedevelopmentandcomparisonversion2peerreview2approved AT francescadapporto avalidatedandstandardizedpseudotypedmicroneutralizationassayasasafeandpowerfultooltomeasurelassavirusneutralisingantibodiesforvaccinedevelopmentandcomparisonversion2peerreview2approved AT mariaaltamura avalidatedandstandardizedpseudotypedmicroneutralizationassayasasafeandpowerfultooltomeasurelassavirusneutralisingantibodiesforvaccinedevelopmentandcomparisonversion2peerreview2approved AT nigeltemperton avalidatedandstandardizedpseudotypedmicroneutralizationassayasasafeandpowerfultooltomeasurelassavirusneutralisingantibodiesforvaccinedevelopmentandcomparisonversion2peerreview2approved AT pietropiu avalidatedandstandardizedpseudotypedmicroneutralizationassayasasafeandpowerfultooltomeasurelassavirusneutralisingantibodiesforvaccinedevelopmentandcomparisonversion2peerreview2approved AT claudiasemplici avalidatedandstandardizedpseudotypedmicroneutralizationassayasasafeandpowerfultooltomeasurelassavirusneutralisingantibodiesforvaccinedevelopmentandcomparisonversion2peerreview2approved AT eleonoramolesti avalidatedandstandardizedpseudotypedmicroneutralizationassayasasafeandpowerfultooltomeasurelassavirusneutralisingantibodiesforvaccinedevelopmentandcomparisonversion2peerreview2approved AT vittoriaforconi avalidatedandstandardizedpseudotypedmicroneutralizationassayasasafeandpowerfultooltomeasurelassavirusneutralisingantibodiesforvaccinedevelopmentandcomparisonversion2peerreview2approved AT robertaantonelli avalidatedandstandardizedpseudotypedmicroneutralizationassayasasafeandpowerfultooltomeasurelassavirusneutralisingantibodiesforvaccinedevelopmentandcomparisonversion2peerreview2approved AT alessandromanenti validatedandstandardizedpseudotypedmicroneutralizationassayasasafeandpowerfultooltomeasurelassavirusneutralisingantibodiesforvaccinedevelopmentandcomparisonversion2peerreview2approved AT emanuelemontomoli validatedandstandardizedpseudotypedmicroneutralizationassayasasafeandpowerfultooltomeasurelassavirusneutralisingantibodiesforvaccinedevelopmentandcomparisonversion2peerreview2approved AT francescadapporto validatedandstandardizedpseudotypedmicroneutralizationassayasasafeandpowerfultooltomeasurelassavirusneutralisingantibodiesforvaccinedevelopmentandcomparisonversion2peerreview2approved AT mariaaltamura validatedandstandardizedpseudotypedmicroneutralizationassayasasafeandpowerfultooltomeasurelassavirusneutralisingantibodiesforvaccinedevelopmentandcomparisonversion2peerreview2approved AT nigeltemperton validatedandstandardizedpseudotypedmicroneutralizationassayasasafeandpowerfultooltomeasurelassavirusneutralisingantibodiesforvaccinedevelopmentandcomparisonversion2peerreview2approved AT pietropiu validatedandstandardizedpseudotypedmicroneutralizationassayasasafeandpowerfultooltomeasurelassavirusneutralisingantibodiesforvaccinedevelopmentandcomparisonversion2peerreview2approved AT claudiasemplici validatedandstandardizedpseudotypedmicroneutralizationassayasasafeandpowerfultooltomeasurelassavirusneutralisingantibodiesforvaccinedevelopmentandcomparisonversion2peerreview2approved AT eleonoramolesti validatedandstandardizedpseudotypedmicroneutralizationassayasasafeandpowerfultooltomeasurelassavirusneutralisingantibodiesforvaccinedevelopmentandcomparisonversion2peerreview2approved AT vittoriaforconi validatedandstandardizedpseudotypedmicroneutralizationassayasasafeandpowerfultooltomeasurelassavirusneutralisingantibodiesforvaccinedevelopmentandcomparisonversion2peerreview2approved AT robertaantonelli validatedandstandardizedpseudotypedmicroneutralizationassayasasafeandpowerfultooltomeasurelassavirusneutralisingantibodiesforvaccinedevelopmentandcomparisonversion2peerreview2approved |